CGEN
Compugen Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.97
+0.51%Year over year
Reported trailing growth
- Revenue
- +234.2%
- EBITDA
- +301.4%
- EBIT
- +252.9%
- EPS
- +278.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -91.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +113.3%
- EBITDA
- +490.4%
- EBIT
- +310.4%
- Net income
- +348.4%
- EPS
- +337.5%
- Free cash flow
- -36.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026